Deciphering non-genetic determinants and targetability of cancer cell plasticity.

This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment.

Subsidie
€ 2.000.000
2025

Projectdetails

Introduction

Cancer cell plasticity, the ability of cancer cells to change their identity, enables tumors to adapt to hostile environments, aiding metastasis and resistance to treatments. Hence, plasticity is a major unsolved problem frustrating effective treatment. Unraveling the mechanisms underlying cancer cell plasticity is crucial to establish new avenues for cancer therapy.

In contrast to adult cancers, many pediatric tumors are driven by a single genetic alteration that fuels their aggressive nature through remarkable plasticity. Despite their differences, pediatric cancers offer a unique platform to investigate cancer cell plasticity due to their genetically clear characteristics. I hypothesize that plasticity can be reversed to differentiate tumor cells and “mature cancer”.

Goal

Building upon previous ERC-StG funding, we have successfully utilized organoid technology, single-cell genomics, and lineage tracing approaches to uncover the origins of various pediatric cancers. Our findings revealed that these cancers exhibit robust yet pharmacologically reversible plasticity at the level of the epigenome.

The goal of this proposal is to reverse cell state changes during tumorigenesis to “mature cancer”.

Approach

We will:

  1. Apply advanced (spatial) single-cell transcriptomics and epigenomics approaches to a unique cohort of pediatric tumors and metastases to map out cell state changes during disease progression.
  2. Utilize our unique pediatric cancer organoids to interrogate and target hierarchical trajectories with the aim to mature cancer.
  3. Screen the enhancer-ome to identify non-genetic determinants of cancer cell plasticity.

Innovation

Integrating these cutting-edge technologies on patient-derived tissues and organoids will uncover fundamental principles governing cancer cell plasticity. The research will pioneer innovative methodologies and reveal strategies for identifying cancer maturation targets, advancing cancer therapy research.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.000.000
Totale projectbegroting€ 2.000.000

Tijdlijn

Startdatum1-6-2025
Einddatum31-5-2030
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BVpenvoerder

Land(en)

Netherlands

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

A multiplexed biomimetic imaging platform for assessing single cell plasticity (Plastomics) and scoring of tumour malignancy

The PLAST_CELL project aims to develop a microfluidics-based imaging platform to quantify cancer cell plasticity, enhancing diagnosis and treatment of metastasis and therapy resistance.

€ 2.982.792
ERC STG

Oncogenic competence during development – When, Where and Why?

This project aims to uncover the origins and transformation mechanisms of malignant rhabdoid tumors through advanced genomic and imaging techniques, with the goal of developing targeted treatments.

€ 1.499.943
ERC STG

Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and Diagnosis

EpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors.

€ 1.500.000
ERC STG

Understanding and targeting cancer persister cells

This project aims to develop tools for studying cancer persister cells using single-cell lineage tracing to enhance understanding and treatment of therapy-resistant tumors.

€ 1.728.750